RESULTS	In LUX-Lung 3 , median overall survival was 28.2 months ( 95 % CI 24.6-33 .6 ) in the afatinib group and 28.2 months ( 20.7-33 .2 ) in the pemetrexed-cisplatin group ( HR 0.88 , 95 % CI 0.66-1 .17 , p = 0.39 ) .\